Hyderabad, Telangana, India – Business Wire India – GV Research Platform (GVRP), a leading provider of preclinical research solutions, has entered into a strategic partnership with BeCytes Biotechnologies, aiming to enhance access to high-quality biological materials for drug discovery and toxicology research in India.
The collaboration will provide Indian researchers with specialized biological tools, leveraging BeCytes’ expertise in tissue procurement, primary cell isolation, and in vitro models. This partnership will ensure that cutting-edge resources are available for more predictive and translational studies. As part of this initiative, GVRP will offer cryopreserved hepatocytes, hepatic and skin cells, subcellular fractions, and customized cell isolation services—key components for drug metabolism, safety assessments, and disease modeling.
BeCytes Biotechnologies, based in Barcelona, Spain, has earned a global reputation for providing reliable human and animal-derived cells to researchers. Their in-depth knowledge of cell characterization and in vitro model development ensures consistency, a crucial factor in preclinical drug screening and toxicology studies.
With its AAALAC International accredited and OECD-GLP compliant facilities situated in Genome Valley, Hyderabad, GVRP is strategically positioned to distribute BeCytes' offerings across India. This collaboration further solidifies both companies’ commitment to enhancing the reproducibility and quality of preclinical research, which in turn will foster innovation and support drug development efforts in India and beyond.
The collaboration will provide Indian researchers with specialized biological tools, leveraging BeCytes’ expertise in tissue procurement, primary cell isolation, and in vitro models. This partnership will ensure that cutting-edge resources are available for more predictive and translational studies. As part of this initiative, GVRP will offer cryopreserved hepatocytes, hepatic and skin cells, subcellular fractions, and customized cell isolation services—key components for drug metabolism, safety assessments, and disease modeling.
Bridging Innovation and Accessibility
Kalyan Korisapati, Co-Founder & Group CEO of GVRP, emphasized the importance of this partnership in addressing the challenges within India’s expanding biomedical research sector. "As India’s biomedical research landscape continues to grow, high-quality biological models remain a significant challenge. By collaborating with BeCytes, we are bridging this gap, providing researchers with top-tier hepatic cell models, including advanced disease models like NASH and Liver 3D Spheroids functional models," he said. "This collaboration will facilitate the advancement of discoveries and innovations in India."BeCytes Biotechnologies, based in Barcelona, Spain, has earned a global reputation for providing reliable human and animal-derived cells to researchers. Their in-depth knowledge of cell characterization and in vitro model development ensures consistency, a crucial factor in preclinical drug screening and toxicology studies.
A Vision for Empowering Preclinical Research in India
Jordi Xapellí, CEO of BeCytes Biotechnologies, expressed enthusiasm about the partnership. "We are thrilled to work with GVRP to expand our global reach and provide researchers in India with reliable, cell-based solutions. GVRP’s established presence and commitment to excellence will significantly contribute to advancing scientific research," he stated.With its AAALAC International accredited and OECD-GLP compliant facilities situated in Genome Valley, Hyderabad, GVRP is strategically positioned to distribute BeCytes' offerings across India. This collaboration further solidifies both companies’ commitment to enhancing the reproducibility and quality of preclinical research, which in turn will foster innovation and support drug development efforts in India and beyond.
Last updated by a enewsx:
